Workflow
Theratechnologies(THTX)
icon
Search documents
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
GlobeNewswire News Room· 2024-09-26 11:30
MONTREAL, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2024, on Thursday, October 10 at 8:30 a.m. ET. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. He will be joined by o ...
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
GlobeNewswire News Room· 2024-09-17 21:00
Core Viewpoint - Theratechnologies Inc. announced a potential temporary supply disruption for EGRIFTA SV® due to a voluntary shutdown of its contract manufacturer's facility following an FDA inspection, which may impact revenue in fiscal year 2024 [1][4]. Group 1: Supply Disruption Details - The shutdown is expected to last three months and is not related to the manufacturing process of EGRIFTA SV®, but rather to the manufacturing environment [4]. - The manufacturer plans to resume activities by mid-October 2024, with a new batch of EGRIFTA SV® scheduled for production on October 21, 2024 [4][5]. Group 2: Financial Impact - The company estimates a revenue shortfall of approximately US$1.6 million from EGRIFTA SV® for fiscal year 2024 due to inventory management measures [2]. - Despite the anticipated revenue impact in Q4 2024, the company remains on track to deliver a strong Adjusted EBITDA for the current fiscal year [3]. Group 3: Regulatory Compliance - To resume distribution, the company is required to file a Prior Approval Supplement (PAS) with the FDA, which is expected to be submitted around the manufacturing date [5]. - The FDA will review the PAS within four months of receipt, and the company will provide updates on any material developments [5].
Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value Investors
ZACKS· 2024-08-01 13:51
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time. Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phas ...
Theratechnologies(THTX) - 2024 Q2 - Earnings Call Transcript
2024-07-10 14:05
Operator Theratechnologies Inc. (NASDAQ:THTX) Earnings Conference Call July 10, 2024 8:30 AM ET Company Participants John Leasure - Global Commercial Officer Paul Levesque - President & CEO Philippe Dubuc - SVP & CFO Christian Marsolais - SVP & Chief Medical Officer Conference Call Participants Andre Uddin - Research Capital Justin Walsh - JonesTrading Carvey Leung - Cantor Fitzgerald Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies Second Quarter 2024 ...
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
Newsfilter· 2024-06-26 11:30
Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below. About Theratechnologies Investor inquiries: Philippe Dubuc Senior Vice President and Chief Financial Officer pdubuc@theratech.com 438-315-6608 The call will be hosted by Paul Lévesque, President and Chief Executive Officer. He will be joined by other members of the management team, including Philippe Dubuc, Senior Vice President and Chief Financial ...
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
GlobeNewswire News Room· 2024-06-26 11:30
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its second quarter ended May 31, 2024, on Wednesday, July 10 at 8:30 a.m. ET. CONFERENCE CALL INFORMATION Conference Call Date July 10, 2024 Conference Call Time 8:30 a.m. ET Webcast lin ...
Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum
ZACKS· 2024-06-05 13:51
Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point, as stocks may lose momentum when their valuations exceed future growth potential [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [3] Group 2: Theratechnologies (THTX) Stock Analysis - Theratechnologies (THTX) has shown a four-week price change of 2%, indicating growing investor interest [4] - THTX has gained 5% over the past 12 weeks, with a beta of 1.43, suggesting it moves 43% more than the market [5] - THTX has a Momentum Score of B, indicating a favorable time to invest based on momentum [6] - The stock has a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which attract more investors [7] - THTX is trading at a Price-to-Sales ratio of 0.74, suggesting it is undervalued at 74 cents for each dollar of sales [7] Group 3: Additional Investment Opportunities - Besides THTX, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [9]
Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Newsfilter· 2024-05-23 21:00
MONTREAL, May 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced Phase 1 data demonstrating signs of long-term efficacy and a manageable safety profile of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), in patients with solid tumors. The data will be presented in a poster sessi ...
Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
globenewswire.com· 2024-05-23 21:00
Core Insights - Theratechnologies Inc. announced promising Phase 1 data for its investigational peptide drug conjugate, sudocetaxel zendusortide (TH1902), showing long-term efficacy and manageable safety in patients with solid tumors [1][2][9] Study Results - The updated analysis from the Phase 1 clinical trial indicated durable disease stabilization lasting up to 45 weeks after treatment completion, with a clinical benefit rate of 44% in female cancers [2][5] - Sudocetaxel zendusortide demonstrated a unique mechanism of action, including immune cell infiltration in "cold" tumor models and targeting chemotherapy-resistant cancer stem cells [2][7] - The safety profile of sudocetaxel zendusortide was manageable, with few Grade 3 adverse events reported at a dosage of 300 mg/m² [2][6] Clinical Trial Details - The Phase 1 trial consists of three parts: Part 1 focused on safety and tolerability with 18 patients, Part 2 involved dose expansion with another 18 patients, and Part 3 is ongoing for dose optimization in platinum-resistant ovarian cancer [4][10] - The study included patients with prior exposure to taxane-containing regimens, highlighting the significance of the results in a heavily pretreated population [5] Pharmacokinetics - Pharmacokinetic measures showed that exposure to free docetaxel was significantly lower than that for sudocetaxel zendusortide, which may explain the reduced incidence and severity of adverse events [8] - The maximum concentration (Cmax) of sudocetaxel zendusortide was 30.4 μM, compared to 0.58 μM for free docetaxel, indicating a favorable pharmacokinetic profile [8] Company Overview - Theratechnologies is focused on developing innovative therapies to address unmet medical needs, with sudocetaxel zendusortide being the first compound from its SORT1+ Technology™ platform targeting sortilin receptors in various cancers [10][11][12]
Theratechnologies(THTX) - 2024 Q1 - Earnings Call Transcript
2024-04-10 14:47
Financial Data and Key Metrics - Consolidated revenue for Q1 2024 was below expectations, but the company recorded its third straight quarter of near flat to positive adjusted EBITDA, an improvement of $3.6 million over Q1 2023 [10] - Adjusted EBITDA for Q1 2024 was negative $247,000, a significant improvement from negative $3.9 million in the same period last year [40] - The company reaffirmed its 2024 guidance for revenues between $87 million and $90 million and adjusted EBITDA in the range of $13 million to $15 million [68] Business Line Data and Key Metrics - EGRIFTA SV net sales in Q1 2024 were $9.6 million, down from $12.7 million in Q1 2023, primarily due to inventory realignment at pharmacy partners [69] - Trogarzo net sales in Q1 2024 were $6.7 million, a 7.4% decrease year-over-year, mainly due to lower unit sales [38] - New prescription growth for EGRIFTA SV continued with new enrollments up 21% and unique patients up 14% compared to Q1 2023 [5] Market Data and Key Metrics - The number of unique prescribers for EGRIFTA SV increased by 13% in February 2024 compared to the same month in 2023 [5] - Inventory on hand at the end of Q1 2024 was 27 days, down from 55 days at the end of Q1 2023, impacting Q1 revenues and growth [6] Company Strategy and Industry Competition - The company is focusing on commercial capabilities, completing Part 3 of its Phase I oncology clinical trial, and acquiring assets to create shareholder value [26] - The company is actively monitoring its distribution network to maintain 30 to 35 days of inventory on hand at the pharmacy level [6] - The company has decided to deprioritize the Intramuscular Administration of Trogarzo due to the cost of a new study and the evolving competitive landscape [34] Management Commentary on Operating Environment and Future Outlook - Management expects a stronger Q2 2024 compared to the unusually weak Q2 2023 and anticipates more stable revenue growth in the second half of the year [32] - The company remains confident in its strategy and expects to see improved cash flow and value for shareholders [68] - Management highlighted the promising tolerability and anti-tumor effects of its new PDCs, demonstrating the versatility of its SORT1+ technology platform [8] Other Important Information - The company ended Q1 2024 with $38.5 million in cash, bonds, and money market funds [57] - R&D expenses decreased by 60% in Q1 2024 compared to the same period last year, primarily due to lower spending on the oncology program [39] - G&A expenses decreased by 15% in Q1 2024 compared to the same period last year, reflecting the company's focus on controlling expenses [56] Q&A Session Summary Question: Status of business development efforts and hurdles - The company is actively seeking to acquire new assets and is optimistic about positive outcomes within a decent period of time [78] Question: Impact of GLP-1s on EGRIFTA - EGRIFTA continues to perform well despite the pressure from GLP-1s, with strong new enrollment and patient growth [24][82] Question: Plan with Marathon facility - The company has $60.6 million drawn on the Marathon facility, with repayment beginning in August 2024 over 36 monthly installments [25][41] Question: TH1902 patient enrollment and data timeline - The company is enrolling six patients at a higher dose level for TH1902 and expects to complete recruitment in the coming weeks or months [64][72] Question: NASH partnership discussions - The company has seen increased interest in tesamorelin for NASH following the approval of a competing product and is advancing a Phase IIb/III trial protocol [65] Question: Adjusted EBITDA focus and future metrics - The company expects to transition from focusing on adjusted EBITDA to discussing cash flow and net income in the next quarter or two [51] Question: FDA meeting and resubmission plan - The company clarified two key questions with the FDA during a Type A meeting and expects to resubmit for a decision before the end of 2024 [66][81]